ArticleAmerican heart journal plus : cardiology research and practice2025
Sodium-glucose cotransporter 2 inhibitors for wild-type transthyretin amyloidosis: Insights from a global database.
Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wild-type transthyretin amyloidosis (wtATTR) is an increasingly recognised cause of infiltrative cardiomyopathy, particularly in the elderly population. The use of traditional heart failure prognostic therapies in this group may be limited by age-associated comorbidities and heightened vulnerability to changes in renal function and blood pressure. We aimed to assess the potential prognostic impact of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in wtATTR. Methods: Using data from a federated global electronic medical record database (TriNetX), patients diagnosed with wtATTR between 2005 and 2025 were identified and followed for up to 5 years. Patients were stratified into two groups based on SGLT2i use with 1:1 propensity score matching (PSM) between the cohorts. The primary outcome was all-cause mortality, and secondary outcome was clinical decompensation for heart failure. Results: A total of 1,160 patients treated with SGLT2i and 2,325 patients without SGLT2i met inclusion criteria for the study. After PSM, each group contained 909 patients with comparable covariates. Mean age was 77.3±9.2 years (81.4% male) in the treatment group and 77.9±7.5 years (82.5% male) for control. Median follow-up was 297 days in the treatment group and 438 days in the control group. Patients treated with SGLT2i had lower all-cause mortality (hazard ratio [HR] 0.62; 95% CI 0.49-0.79) and clinical decompensation for heart failure (odds ratio [OR] 0.61; 95% CI 0.40-0.94). Conclusion: SGLT2i use was associated with better survival and a lower incidence of clinical heart failure. These findings signal a potential prognostic benefit of SGLT2i in wtATTR that should be explored further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.